Vienna-based PIUR IMAGING, a medical device company innovating AI-powered tomographic 3D ultrasound, today announced the successful closing of a €5.6 million growth capital funding round.
The round was led by Aescuvest Capital Partners, a leading healthcare investment in Germany.
“Ultrasound is one of the most valuable imaging modalities – flexible, safe, and affordable. But its greatest limitation remains user-dependency, as most conclusions are drawn from 2D slices that vary by operator,” said Frederik Bender, Managing Director & CEO of PIUR IMAGING. “By adding a third dimension, we eliminate much of that variability – shifting from subjective snapshots to comprehensive, organ-level imaging that enables AI to perform more consistent and reliable analysis.
“This investment allows us to bring this vision to scale. It empowers us to grow our commercial footprint, especially in the U.S., expand our product integration with global ultrasound leaders, and continue developing clinical applications that improve patient outcomes. We’re not just adding technology – we’re changing the standard of care.”
Founded in 2014, PIUR IMAGING is an ISO-13485 certified and FDA-cleared medical device company, specialising in advanced tomographic 3D ultrasound solutions. Their mission is to improve diagnostic workflows and enhance patient care by offering innovative add-on solutions for existing ultrasound devices, empowering clinicians with accurate, reproducible imaging for optimal patient outcomes.
The company’s proprietary sensor reportedly transforms standard 2D ultrasound systems into high-performance 3D imaging platforms – enabling entire organs and anatomical structures to be captured in a single scan. Coupled with AI-based image analysis and volumetric measurements, this advancement empowers clinicians to deliver faster, more objective, and more reproducible diagnoses across a broad range of clinical applications.
“PIUR’s approach is elegant in its simplicity. Rather than reinventing the wheel, they unlock new value from existing ultrasound systems with a seamless add-on solution,” said Christoph Bartoschek, Investment Principal at Aescuvest Capital Partners. “This lowers the adoption barrier significantly – users understand it immediately, and the clinical benefits are clear.”
Following recent FDA clearance and the establishment of a U.S. subsidiary, the new funding will fuel the company’s commercial expansion, particularly in the United States.
Growth will be driven by two core products: PIUR tUS Infinity , a vendor-neutral add-on that turns any existing 2D ultrasound into a 3D device, and PIUR tUS inside, an integrated solution directly embedded into select GE HealthCare LOGIQ scanners.
“What excites us as investors is the clarity of the value proposition and the company’s strong foundation. PIUR has already built a loyal customer base in the DACH region, signed agreements with respected partners in the imaging ecosystem, and assembled a team with a focused vision for scaling across clinical indications and geographies.
“The recent FDA clearance of the tUS inside makes this an ideal time to invest, aligning perfectly with our strategy of targeting opportunities approaching key regulatory milestones,” Bartoschek added.
As healthcare systems around the world seek to improve diagnostic access and efficiency, PIUR’s tomographic 3D ult rasound offers a potentially transformative answer.